Stoke Therapeutics CEO Edward Kaye To Step Down

(RTTNews) - Biotechnology company Stoke Therapeutics, Inc. (STOK) announced Tuesday that Edward Kaye has decided to step down from his role as Chief Executive Officer effective as of March 19, 2025. Kaye will serve as an advisor to the company to facilitate a smooth transition and will continue to serve as a Director on Stoke's Board.

Effective March 19, 2025, Ian Smith has been appointed Interim Chief Executive Officer. The current Chairman of the Board Arthur Tzianabos has been appointed Interim Executive Chairman. He will support Smith and Kaye through the transition and lead the search for a permanent Chief Executive Officer.

Kaye has served as Stoke's CEO and Director since 2017. Prior to that, he joined Sarepta Therapeutics as Chief Medical Officer in 2011 and went on to serve as CEO of Sarepta in 2015. He also served on Sarepta's Board of Directors. Earlier, he spent 10 years at Genzyme Corp., most recently as group vice president of clinical development.

Meanwhile, Smith is a biotechnology leader with more than 20 years of finance and operations experience. He has served as a member of Stoke Therapeutics' Board of Directors since September 2023. He currently serves as a senior advisor to Bain Capital Life Sciences since January 2021.

Smith previously served as Executive Vice President and Chief Operating Officer, and Chief Financial Officer of Vertex Pharmaceuticals between 2001 and 2019. Prior to 2001, Smith was a partner in the Life Science and Technology Practice of the accounting firm Ernst & Young LLP.